LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into a multi-year exclusive U.S. agreement with Cardinal Health (NYSE: CAH),. Under the agreement, Cardinal Health will have exclusive rights to sell T2 Biosystems’ FDA-cleared direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens, including the T2Dx® ...

Transaction demonstrates Cardinal Health's continued strategic investment in specialty and oncology, underscores commitment to independent community healthcare providers Accelerates the development of Navista oncology practice alliance, adding more than 100 providers at more than 50 community-based sites delivering broad-reaching oncology and urology care across 10 states DUBLIN, Ohio, Sept. 20, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that it has entered into a definitive agreement ...

The latest trading session saw Cardinal Health (CAH) ending at $110.76, denoting a -0.58% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily gain of 1.7%. Elsewhere, the Dow gained 1.26%, while the tech-heavy Nasdaq added 2.51%.Shares of the prescription drug distributor have appreciated by 1.61% over the course of the past month, outperforming the Medical sector's gain of 1.53% and the S&P 500's gain of 1.27%.Market participants will be closely following the finan ...

Cardinal Health (CAH) and Australia-based Telix recently entered a deal, selecting CAH as a commercial radiopharmaceutical distributor to supply finished unit doses of Telix's PET agent, Zircaix, for the imaging of kidney cancer in the United States, subject to regulatory approval.Telix and Cardinal Health already have a contract in place under which CAH has successfully commercialized Telix’s PSMA-PET imaging, Illuccix, approved for diagnosing prostate cancer in men.Likely Trend of CAH Stock Following the ...

Cardinal Health (CAH) closed the latest trading day at $113.28, indicating a +0.1% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.13% for the day. Elsewhere, the Dow saw an upswing of 0.55%, while the tech-heavy Nasdaq depreciated by 0.52%. The prescription drug distributor's shares have seen an increase of 3.02% over the last month, not keeping up with the Medical sector's gain of 3.34% and the S&P 500's gain of 3.67%. The investment community will ...

- Increase in endogenous cortisol production achieved in all patients in higher dose cohorts of BBP-631, a result seen for the first time ever in CAH patients - The gene therapy was well tolerated with no treatment-related serious adverse events (SAEs) reported - Despite novel scientific advancements achieved with this program, the data do not warrant additional capital investment at this time and the gene therapy budget is being significantly reduced PALO ALTO, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Br ...

Cardinal Health, Inc. (NYSE:CAH) Baird's 2024 Global Healthcare Conference September 10, 2024 9:05 AM ET Company Participants Matt Sims - VP, IR Jason Hollar - CEO Aaron Alt - CFO Conference Call Participants Eric Coldwell - Baird Eric Coldwell Good morning, everyone. My name is Eric Coldwell. I cover pharma services, healthcare and distribution, a broad list of related healthcare business service type entities, and it's a great pleasure to have Cardinal Health with us here today. Before we get going, I'm g ...

Core Insights - Cardinal Health has demonstrated strong financial performance over the past two years, with nearly 50% cumulative earnings per share growth and approximately $7 billion in cumulative adjusted free cash flow [5][10]. Company Strategy and Performance - The company has focused on simplifying its operations and investing in key growth areas, particularly in its pharmaceutical segment, which has seen significant strategic prioritization [6][8]. - Cardinal Health has transitioned from a defensive to an offensive strategy, emphasizing organic growth and M&A activities, particularly in the specialty business [12][54]. - The specialty business has grown from $32 billion to $36 billion, reflecting a 14% compound annual growth rate (CAGR) over the last four years [17]. M&A and Growth Initiatives - The acquisition of Specialty Networks is a key component of Cardinal Health's strategy to enhance its specialty business, providing access to new therapeutic areas and advanced technology [18][19]. - The company is also investing heavily in its nuclear and precision health solutions, with a focus on Theranostics, expecting continued growth in this area [50]. Financial Guidance and Cash Flow - Cardinal Health has set a profit target of $175 million for fiscal year 2025 and $300 million for fiscal year 2026, indicating confidence in its operational improvements [10][37]. - The company has increased its guidance for share repurchases to $750 million for fiscal year 2025, up from a previous commitment of $500 million [57]. Market Position and Competitive Landscape - Cardinal Health maintains a strong position in the acute care market, benefiting from relationships with large healthcare systems and a focus on customer retention [31][32]. - The company is adapting to market changes, including the impact of Medicaid disenrollment and competitive pressures from other distributors [30]. Supply Chain and Operational Resilience - Cardinal Health has built a resilient supply chain to manage inflation and freight costs, allowing it to maintain its profit targets despite rising costs [36][41]. - Investments in domestic manufacturing, particularly for syringes, are expected to enhance revenue and profitability in the near term [44].

WASHINGTON and DUBLIN, Ohio, Sept. 10, 2024 /PRNewswire/ -- In observance of today's World Suicide Prevention Day, Children's Hospital Association (CHA), Cardinal Health (NYSE: CAH), and Zero Suicide Institute (ZSI) celebrate early success of the Preventing Youth Suicide Collaborative, a collaborative funded by the Cardinal Health Foundation, led by CHA, and informed by ZSI's prevention expertise.Since 2022, 30 children's hospitals have focused on early detection and intervention, sharing innovative strateg ...

Cardinal Health (CAH) closed at $112.80 in the latest trading session, marking a +0.92% move from the prior day. This change lagged the S&P 500's 1.16% gain on the day. Elsewhere, the Dow saw an upswing of 1.2%, while the tech-heavy Nasdaq appreciated by 1.16%.The the stock of prescription drug distributor has risen by 11.03% in the past month, leading the Medical sector's gain of 4.5% and the S&P 500's gain of 3.48%.The investment community will be closely monitoring the performance of Cardinal Health in i ...